Abstract 51P
Background
Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13. Fractionations to investigate early and four year late side effects of hypofractionated postmastectomy radiation therapy (HFRT-PM) of 39 Gy in 13 fractions over 3 weeks.
Methods
We retrospectively analyzed characteristics and outcomes of patients with stage II to III breast cancer treated with HFRT-PM between February 2019 and February 2023 during the COVID-19 pandemic. The selected patients did not have any previously diagnosed heart or lung disease. Treatment provided in 13 fractions of 3 Gy per fraction. The treatment techniques were applied by using 3-dimensional conformal radiation therapy and IMRT of the chest wall with regional nodal volume if required. The end point was freedom from any grade 3 or higher toxicities.
Results
We identified 730 patients with a median follow-up of 4 year. About two-third of the patient (66.6%) had the disease located in the left side. Regional nodal irradiation was done in 84.1% of patients. In multivariate analysis, regional lymph node involvement (≥4 nodes) was associated with worse locoregional control (hazard ratio, 1.68; 95% confidence interval, 1.06-2.67; P = .03) and overall survival (hazard ratio, 2.16; 95% confidence interval, 1.59-2.95; P < .001). The toxicities were acceptable. After a four-year follow -up, there are no grade 3 or 4 toxicities. The incidence of early skin reactions (13% grade 2) cardiac disorders (1.5%), and symptomatic lung fibrosis (1.7%) was low during follow-up. The cumulative rate of arm lymphedema was 2.1% and considered severe in 40 patients (0.05%).
Conclusions
The early results of this study show that HFRT-PM of 39 Gy in 13 fractions over 3 weeks seems safe, but long-term results need to be observed and highlighting the need for long-term follow-up and for randomized trials for hypofractionated radiation therapy postmastectomy especially for young patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract